MBX Stock — MBX Biosciences, Inc.

MBX Biosciences, Inc. (MBX)

Updated October 16, 2026.

MBX is a Stock. Total return is 210.1% over the past 2.1 years, 170.0 points ahead of SPY at 40.1%.

MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, with lead programs in Phase 2 and Phase 3 trials for chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage drug development, as the company has no approved products and remains dependent on clinical trial success and capital availability.

MBX performance versus SPY

Price and return data through 2026-10-16.

Total return is 210.1% over the past 2.1 years, 170.0 points ahead of SPY at 40.1%. Over the past year its total return — price change plus distributions reinvested — is 260.3%. Its deepest 1-year drawdown was 37.6%.

MBX key facts

Asset type

Stock

Asset class

Equity

Inception date

09/12/2024

Distribution frequency

None

Last close

$49.61 (as of 2026-10-16)

Market cap

$2,389,222,363

Average volume

818907.0

Beta

0.103

Payout ratio

0.0%

EPS

$-2.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MBX risks and drawbacks

The deepest 1-year drawdown on record here is 37.6%.

Who may consider MBX — and who may not

It is a weaker fit for investors who need monthly cash flow (MBX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MBX

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions